Alnylam Pharmaceuticals (NASDAQ:ALNY) Hits New 52-Week High - What's Next?

Key Points

• Alnylam Pharmaceuticals stock reached a new 52-week high of $485.28, reflecting strong investor interest and trading volume of 294,055 shares.
• The company reported a quarterly revenue increase of 17.3% to $773.69 million and an earnings per share (EPS) of $0.32, exceeding expectations significantly.
• A wave of analyst upgrades has occurred, with a consensus rating of "Moderate Buy" and a revised price target averaging $457.08 following recent positive performance.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) reached a new 52-week high during mid-day trading on Wednesday . The stock traded as high as $485.28 and last traded at $482.34, with a volume of 294055 shares. The stock had previously closed at $469.36.

Analyst Upgrades and Downgrades

ALNY has been the topic of several recent research reports. Wolfe Research raised shares of Alnylam Pharmaceuticals from an "underperform" rating to a "peer perform" rating in a report on Monday, August 4th. JPMorgan Chase & Co. dropped their price target on shares of Alnylam Pharmaceuticals from $475.00 to $473.00 and set an "overweight" rating for the company in a research report on Monday. Canaccord Genuity Group increased their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Morgan Stanley raised their target price on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an "equal weight" rating in a research report on Monday, October 6th. Finally, The Goldman Sachs Group raised their target price on shares of Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a "buy" rating in a research report on Tuesday, September 16th. Twenty-four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $457.08.

Alnylam Pharmaceuticals Trading Up 1.5%

The firm has a market capitalization of $62.45 billion, a P/E ratio of -193.25 and a beta of 0.36. The stock's 50-day simple moving average is $453.28 and its two-hundred day simple moving average is $348.35. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last released its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 EPS for the quarter, topping the consensus estimate of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The firm had revenue of $773.69 million for the quarter, compared to the consensus estimate of $633.54 million. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. The company's quarterly revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, Director Colleen F. Reitan sold 18,000 shares of the company's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $467.60, for a total value of $8,416,800.00. Following the completion of the transaction, the director directly owned 775 shares of the company's stock, valued at $362,390. This represents a 95.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Dennis A. Ausiello sold 31,448 shares of the company's stock in a transaction that occurred on Thursday, August 14th. The stock was sold at an average price of $436.58, for a total value of $13,729,567.84. Following the sale, the director owned 911 shares of the company's stock, valued at $397,724.38. This trade represents a 97.18% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 in the last ninety days. 1.20% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. boosted its position in Alnylam Pharmaceuticals by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 13,297,139 shares of the biopharmaceutical company's stock worth $4,336,064,000 after acquiring an additional 240,534 shares during the period. T. Rowe Price Investment Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 0.8% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 4,418,145 shares of the biopharmaceutical company's stock worth $1,192,988,000 after buying an additional 33,696 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Alnylam Pharmaceuticals by 5.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,505,168 shares of the biopharmaceutical company's stock valued at $946,466,000 after purchasing an additional 185,783 shares in the last quarter. Geode Capital Management LLC increased its stake in shares of Alnylam Pharmaceuticals by 3.3% in the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company's stock valued at $779,857,000 after buying an additional 75,936 shares during the period. Finally, Orbis Allan Gray Ltd increased its stake in shares of Alnylam Pharmaceuticals by 29.8% in the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company's stock valued at $691,771,000 after buying an additional 486,489 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.